Efficiency of Intravitreal Ranibizumab Injection in Wet Age-Related Macular Degeneration
Öz
Purpose: To evaluate the efficiency of the treatment of intravitreal ranibizumabin on the functions of lesion size and visual outcome in neovascular age-related macular degeneration cases. Material and Methods: Age-related macular degeneration diagnosis of 71eyes of 59 patients were analyzed retrospectively. Best-corrected visual acuity (BCVA), biomicroscopic examination, intra ocularpressure and fundus examinations were noted about the cases. In order to evaluate the effiency of IVR treatment, widest lesion diameter (WLD) of choroidal neovascularization (CNV) and BCVA were compared statistically, before and after treatment according to fundus fluorescein angiography (FFA). Results: The mean follow-upperiod was 14±5 months. Snellen BCVA was found 0.13±0.09 before treatment and was found 0.22±0.16 after treatment according to Snellen. A statistically significant increase was detected in BCVA after IVR teatment. WLD was calculated 4040±117μm before treatment and 3620±128μm after treatment. After IVR treatment a statistically significant decrease was founded in WLD. Conclusion: In our study, an increase in BCVA and a decrease in WLD were observed with the treatment of IVR in wet AMD cases. IVR was made out to be an effective and safe treatment. It can be thought that an obvious improvement was achieved acording to anatomic and visual acuity.
Anahtar Kelimeler
Kaynakça
- Spaide R. Etiology of late-age-related macular disease. In Alfaro DV. Age-related macular degeneration (A Comprehensive Textbook). Lippincott Williams&Wilkins; 2006;3:23-39.
- Resnikoff S, Pascolini D,Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP et al. Global data on visual impairment in the year 2002. Bulletin of the WHO. 2004;82:844-51.
- Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration; applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol 2007;144:627-37.
- Stewart MW. Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol. 2012;6:1175- 86.
- Börümcek EY. Yaşa Bağlı Maküla Dejeneresansında
- Risk Faktörleri. XXVII. Ulusal Oftalmoloji Kursu; Retina “Güncel Tanı ve Tedavi”, 11–13 Nisan, Ankara. 2008;23-8.
- World Health Organization. Main causes of visual impairment. World Health Organization. Geneva, Erişim:http://www.who.int/blindness/causes/en/index. html. Erişim tarihi: 12.04.2009.
- Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011;12:173-81.
- Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer Wet al.A variable-dosing regimen with intravitreal ranibizumab for neovascular age- relatedmacular degeneration:Year 2 of the PrONTO Study. Am. J. Ophthalmol. 2009;148:43-58.
- Holz FG, Amoaku W, Donate J, Guymer RH, Kellner U, Schlingemann RO et al. Safety and efficacy of a flexible dosing regimen of ranibizumabin neovascular age-related macular degeneration: The SUSTAIN Study. Ophthalmology. 2011;118:663-71.
